‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2  
 
    4 of the best performing pharma & biotech stocks to begin the new year  
 
    The next Neuren? Nyrada chases after two big markets  
 
    This week’s Bulls N’ Bears top ASX runner is … Nyrada.  
 
    Guess which ASX pharmaceuticals stock is up 400% in 2 days  
 
    Nyrada CEO exclusively shares 3 reasons for stunning +420pc session  
 
    Biotech Dispatch: Nyrada reports 'encouraging' early efficacy results from PCSK9i program  

Australian biotech news website, BiotechDispatch said Nyrada had reported "encouraging efficacy results" from an in vivo study involving its NYX-PCSK9i drug candidate.

Read more here

 
    Nyrada (ASX: NYR) CEO James Bonnar discusses the company’s commercialisation plans  
 
    Hypercholesterolaemia Drug Candidate Animation  
 
    Nyrada Brain Injury Explainer Animation